Business Context and Reporting Period
This Form 6-K filing by Sanofi-Synthelabo, dated January 22, 2003, reports consolidated financial results for the full year ended December 31, 2002. The company is a global pharmaceutical firm headquartered in Paris, France. The report highlights a year of substantial sales growth driven by key product launches and strategic acquisitions, specifically the full consolidation of Lorex Pharmaceuticals in the United States.
Key Financial Metrics
Revenue and Sales Growth
- Consolidated Sales (2002): 7,448 million euros.
- Comparable Growth: +12.8% (constant structure and exchange rates).
- Reported Growth: +14.8%.
- Developed Sales: 9,585 million euros (+14.5% comparable), including sales from joint ventures with partners like Bristol-Myers Squibb.
- Fourth Quarter Sales: 1,902 million euros (+11.6% comparable).
Profitability and Margins
- Net Profit Outlook: Management confirms a growth of over 25% in net profit attributable to the Group before exceptional items and goodwill amortization for 2002.
- Margin Data: Specific gross or operating margin percentages are not provided in this filing.
Cash Flow, Debt, and Liquidity
The filing text does not provide specific values for operating cash flow, total debt, or liquidity ratios.
Material Changes vs. Prior Period
Geographical Performance
- Europe: Sales of 4,297 million euros (+11.8% comparable), growing despite cost containment measures in Italy and Germany.
- United States: Sales of 1,689 million euros (+17.5% comparable; +53.7% reported). The reported surge is largely due to the 100% consolidation of Ambien sales starting January 1, 2002, compared to 49% in 2001.
- Rest of World: Sales of 1,462 million euros (+10.3% comparable; -3.4% reported). Reported decline attributed to currency weakness (Japanese yen, Latin American currencies) and a change in consolidation of the Sanofi-Synthelabo Fujisawa joint venture from 100% to 51%.
Product Performance
- Top Performers: Eloxatin (+101.3%), Plavix (+41.5%), Aprovel (+34.0%), and Stilnox/Ambien (+25.5%).
- Declining Products: Corotrope/Primacor (-43.5%) due to generic competition; Ticlid (-33.2%).
- Portfolio Concentration: The top 15 products accounted for 68% of consolidated sales in 2002, up from 64% in 2001.
Outlook, Risks, and Management Commentary
Management Commentary and Highlights
- Acquisitions: Completed acquisition of Pharmacia's 51% interest in Lorex Pharmaceuticals.
- Regulatory Wins: New indications obtained for Plavix (acute coronary syndrome) and Avapro (diabetic nephropathy). Arixtra registered in Europe and launched in the US.
- Patent Protection: A new patent registered for the crystalline polymorphic form 2 of clopidogrel (Plavix), extending protection to 2019.
- Legal Action: Sanofi-Synthelabo initiated proceedings against Apotex and Dr. Reddy Laboratories regarding alleged patent infringement of Plavix in the US.
Risks and Contingencies
- Forward-Looking Statements: Results may differ due to the ability to expand profitably in the US, R&D success, and intellectual property protection.
- Reimbursement Risks: Exposure to healthcare cost reimbursement and pricing reforms, particularly in the US and France.
- Generic Competition: Ongoing threat from generic entrants, specifically noted for Primacor and potential threats to Plavix.
Investor Verification Checklist
- Verify the impact of the 100% consolidation of Lorex Pharmaceuticals on US sales figures versus the prior year's 49% consolidation.
- Confirm the status of the patent litigation against Apotex and Dr. Reddy Laboratories regarding Plavix.
- Assess the sustainability of Eloxatin's growth following its August 2002 US launch.
- Review the specific details of the "over 25%" net profit growth confirmation in the full annual report (Form 20-F) to understand the impact of goodwill amortization and exceptional items.
- Monitor the penetration rate of Arixtra, which the filing notes is slower than expected in its current narrow indication.